San Diego Digestive Diseases Research Center

圣地亚哥消化疾病研究中心

• 批准号: 10617213
• 负责人: LARS ECKMANN
• 金额: $ 118.46万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10617213
• 关键词: Acceleration; Animal Model; Area; Basic Science; Biomedical Research; California; Cell Culture Techniques; Clinical; Clinical Investigator; Clinical Research; Collaborations; Communication; Complement; Development; Digestive System Disorders; Direct Costs; Disease; Effectiveness; Environment; Faculty; Fostering; Funding; Gastrointestinal Diseases; Gastrointestinal tract structure; Goals; Health; Human; Immune response; Immunity; Individual; Infection; Inflammation; Inflammatory; Inflammatory Bowel Diseases; Inflammatory Response; Infrastructure; Institution; Investments; Laboratory Research; Link; Liver; Liver diseases; Mentors; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; Patient Care; Phenotype; Pre-Clinical Model; Prevention; Productivity; R24; Research; Research Personnel; Research Support; Resources; Role; Scientist; Series; Services; Specimen; System; Technology; Translational Research; Universities; Work; base; career; cost effective; design; flexibility; functional genomics; gastrointestinal; high risk; host-microbe interactions; human tissue; improved; innovation; lectures; medical schools; member; microbiome research; mouse model; next generation; novel; patient population; preclinical study; programs; repository; research and development; symposium; web site

Summary The San Diego Digestive Diseases Research Center is founded on a research base of 33 outstanding investigators with current digestive diseases-relevant funding of $15,689,402 in total annual direct costs, of which $5,711,412 (36.4%) are from NIDDK. The overall mission of the Center is to support basic, translational and clinical research that will lead to improved treatment and prevention of inflammatory diseases of the digestive system. The primary goal of the Center is to provide services to the research laboratories of a consortium of four adjacent research institutions in the San Diego area that will foster research productivity and new research directions, and encourage productive collaborations. Another major goal of the San Diego Digestive Diseases Research Center is to enhance new digestive diseases research through Pilot/Feasibility and Enrichment programs. The Center supports three interrelated Biomedical Research Cores that are designed to enhance the research potential and productivity of the Center members. The Human Translational Core builds upon existing expertise in clinical and translational research to provide access to human specimens and leverages unique existing repositories of inflammatory bowel disease and liver diseases. The Preclinical Models Core facilitates and assists in characterizing and understanding of gastrointestinal and liver diseases using murine models. The Microbiomics and Functional Genomics Core provides cutting-edge and cost-effective access to sequencing-based technologies in microbiomics and functional genomics. Furthermore, an Administrative Core supports the Center administratively and coordinates the Pilot/Feasibility and Enrichment programs. Together, these Cores provide high-quality and state-of-the-art research resources to increase collaborative activity and effectiveness of the members, and promote the development of junior investigators. Combined with the Pilot/Feasibility and Enrichment programs, the San Diego Digestive Diseases Research Center will complement a strong cadre of scientists focused on a range of important inflammatory diseases of the gastrointestinal tract and liver. By creating a unique environment to nurture novel research ideas and interactions, the San Diego Digestive Diseases Research Center presents a unique opportunity to integrate clinical and bench research to advance the basic understanding of digestive diseases, and enhance the health and care of patients suffering from those diseases.

概括 圣地亚哥消化疾病研究中心建立在33个杰出的研究基础上 目前的消化疾病相关资金的调查人员为15,689,402美元的年度直接成本， $ 5,711,412（36.4％）来自NIDDK。该中心的整体任务是支持基本的翻译 和临床研究将改善治疗和预防炎症性疾病 消化系统。该中心的主要目标是为一个研究实验室提供服务 圣地亚哥地区四个相邻研究机构的财团将促进研究生产力和 新的研究指示，并鼓励富有成效的合作。圣地亚哥的另一个主要目标 消化疾病研究中心是通过试点/可行性来增强新的消化疾病研究 和丰富计划。该中心支持三个相互关联的生物医学研究核心 旨在提高中心成员的研究潜力和生产力。人类翻译 核心以临床和转化研究的现有专业知识为基础，以提供人类的访问权限 标本和利用炎症性肠病和肝病的独特现有存储库。这 临床前模型核心促进和有助于表征和理解胃肠道和肝脏 使用鼠模型的疾病。微生物学和功能基因组学核心提供了尖端和 对微生物学和功能基因组学中基于测序的技术具有成本效益的访问。 此外，行政核心在行政上支持中心，并协调飞行员/可行性 和丰富计划。这些核心共同提供高质量和最先进的研究资源 提高成员的协作活动和有效性，并促进初级的发展 调查人员。结合飞行员/可行性和丰富计划，圣地亚哥消化疾病 研究中心将补充一批专注于一系列重要炎症的科学家干部 胃肠道和肝脏的疾病。通过创造独特的环境来培养新颖的研究 想法和互动，圣地亚哥消化疾病研究中心为 整合临床和基准研究以提高对消化疾病的基本理解，并增强 患有这些疾病的患者的健康和护理。

项目成果

The compact genome of Giardia muris reveals important steps in the evolution of intestinal protozoan parasites.

• DOI: 10.1099/mgen.0.000402
• 发表时间: 2020-08
• 期刊: Microbial genomics
• 影响因子: 3.9
• 作者: Xu F;Jiménez-González A;Einarsson E;Ástvaldsson Á;Peirasmaki D;Eckmann L;Andersson JO;Svärd SG;Jerlström-Hultqvist J
• 通讯作者: Jerlström-Hultqvist J

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.

• DOI: 10.1111/apt.16712
• 发表时间: 2022-03
• 期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
• 影响因子: 7.6
• 作者: Sandborn, William J.;Lawendy, Nervin;Danese, Silvio;Su, Chinyu;Loftus, Edward V., Jr.;Hart, Ailsa;Dotan, Iris;Damiao, Aderson O. M. C.;Judd, Donna T.;Guo, Xiang;Modesto, Irene;Wang, Wenjin;Panes, Julian
• 通讯作者: Panes, Julian

Characterization of Metronidazole-Resistant Giardia intestinalis Lines by Comparative Transcriptomics and Proteomics.

• DOI: 10.3389/fmicb.2022.834008
• 发表时间: 2022
• 期刊: Frontiers in microbiology
• 影响因子: 5.2
• 作者: Krakovka S;Ribacke U;Miyamoto Y;Eckmann L;Svärd S
• 通讯作者: Svärd S

Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.

• DOI: 10.1111/apt.16626
• 发表时间: 2021-12
• 期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
• 影响因子: 7.6
• 作者: Feagan, Brian G.;Khanna, Reena;Sandborn, William J.;Vermeire, Severine;Reinisch, Walter;Su, Chinyu;Salese, Leonardo;Fan, Haiyun;Paulissen, Jerome;Woodworth, Deborah A.;Niezychowski, Wojciech;Sands, Bruce E.
• 通讯作者: Sands, Bruce E.

(Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-β1/SMAD3 Pathway.

• DOI: 10.1016/j.jcmgh.2021.05.017
• 发表时间: 2021
• 期刊: Cellular and molecular gastroenterology and hepatology
• 影响因子: 7.2
• 作者: Hsieh YC;Lee KC;Lei HJ;Lan KH;Huo TI;Lin YT;Chan CC;Schnabl B;Huang YH;Hou MC;Lin HC
• 通讯作者: Lin HC